In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Although the current clinical formulation of paclitaxel (Taxol) has a promising clinical activity against a wide variety of tumors, it has significant toxic side effects, some of which are associated with its formulation in a 1:1 (v/v) mixture of Cremophor EL and dehydrated alcohol. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water. Our study was designed to evaluate the pharmacokinetics, tissue distribution, toxicity and efficacy of a paclitaxel (Genexol)-containing biodegradable polymeric micellar system (Genexol-PM) in comparison to Taxol. Genexol-PM was newly developed by using a low molecular weight, nontoxic and biodegradable amphiphilic diblock copolymer, monomethoxy poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-PDLLA) and paclitaxel (Genexol, Samyang Genex Co., Seoul, Korea). In a human cancer cell line model, Genexol-PM and Taxol showed comparable in vitro cytotoxicity against human ovarian cancer cell line OVCAR-3 and human breast cancer cell line MCF7. The maximum tolerated dose (MTD) of Genexol-PM and Taxol in nude mice was determined to be 60 and 20 mg/kg, respectively. The median lethal dose (LD(50)) in Sprague--Dawley rats was 205.4 mg/kg (male) and 221.6 mg/kg (female) for Genexol-PM, while 8.3 mg/kg (male) and 8.8 mg/kg (female) for Taxol. After intravenous administration of Genexol-PM in murine B16 melanoma-induced female SPF C57BL/6 mice at a dose of 50 mg/kg, the area under the plasma conc…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The size of polymeric micelles currently in clinical trials are less than 100 nm [6, 7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [6]
In the citing paper
“Genexol® PM consists of paclitaxel in polymeric micelles of mPEG-b-PDLLA (mPEG: 2,000 g/mol, PDLLA: 1,750 g/mol, PDI: 1.0–1.2).”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [6]
In the citing paper
“The micelles are manufactured by the solid dispersion method using the thin film hydration approach and are nano-sized particles with well-defined spherical structure in aqueous media (20–50 nm in diameter and 16.7% LC of paclitaxel) [6].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [6]
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Biodegradable block copolymers as injectable drug-delivery systems
Jeong, B., Bae, Y. H., Lee, D. S., & Kim, S. W. (1997) · Nature · doi:10.1038/42218 · Cited by 1,997
Self-citationRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
Polymeric micelles—A new generation of colloidal drug carriers
Jones, M.-C., & Leroux, J.-C. (1999) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00039-9 · Cited by 1,256
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Polymeric micelles as new drug carriers
Kwon, G. S., & Okano, T. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00401-2 · Cited by 710
Chemistry and Biology of Taxol
Nicolaou, K. C., Dai, W., & Guy, R. K. (1994) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199400151 · Cited by 623
Kataoka, K., Matsumoto, T., Yokoyama, M., Okano, T., Sakurai, Y., Fukushima, S., Okamoto, K., & Kwon, G. S. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00133-9 · Cited by 613
Research works printed but not linked: 3
- 1993, Paclitaxel (Taxol) for ovarian cancer, Med. Lett. Drugs Ther., 35, 39
- Kramer, 1995, Paclitaxel pharmaceutical and pharmacological issues, Eur. Hosp. Pharm., 1, 37
- Presenti, 1995, Synthesis and biological activity of water soluble polymer-bound Taxol derivatives, Proc. Am. Assoc. Cancer Res., 36, 307
Cited by
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
“Compared with Taxol, the maximum tolerable dose of Genexol in mice is three times higher (Kim et al., 2001).”
BackgroundBlock copolymer micelles: preparation, characterization and application in drug delivery
Gaucher, G., Dufresne, M.-H., Sant, V. P., Kang, N., Maysinger, D., & Leroux, J.-C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.034 · Cited by 1,498
“Recently, a novel PEG-b-PDLLA injectable micelle formulation of paclitaxel called GenexolR showed a three-fold increase in the maximum tolerated dose (MTD), while providing much improved antitumor efficacy versus TaxolR in mice [101].”
BackgroundImaging and drug delivery using theranostic nanoparticles
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.004 · Cited by 1,248
Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery
Rapoport, N. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.009 · Cited by 1,002
Metadata
- Authors
- Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H.
- Affiliations
- University of Utah (US)
- Corresponding author
- Seo, Min Hyo
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2001-05
- Volume
- 72
- Issue
- 1-3
- Pages
- 191-202
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2032860131
- Cited by
- 734
- References
- 74
- Citations by year
- 2026: 12 · 2025: 30 · 2024: 33 · 2023: 35 · 2022: 30 · 2021: 24 · 2020: 39 · 2019: 29 · 2018: 35 · 2017: 38 · 2016: 51 · 2015: 50 · 2014: 40 · 2013: 47 · 2012: 33
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- paclitaxel, polymeric micelles, drug toxicity, pharmacokinetics, tissue distribution, antitumor efficacy, ovarian cancer, breast cancer, B16 melanoma, maximum tolerated dose, cytotoxicity
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Antineoplastic Agents, Phytogenic, Drug Carriers, Drug Compounding, Female, Humans, Lethal Dose 50, Male, Mice, Nude, Micelles, Polyethylene Glycols, Polyglycolic Acid, Polymers, Tissue Distribution, Tumor Cells, Cultured, Rats, Sprague-Dawley, Paclitaxel, Lactic Acid, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. https://app.cochat.ai/papers/10.1016/s0168-3659(01)00275-9
- The paper
- Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001). In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. Journal of Controlled Release. https://doi.org/10.1016/s0168-3659(01)00275-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.